The Myelin Disorders Biorepository Project

Adrenoleukodystrophy Clinical Trial

— MDBP  

Official title:

The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03047369
• Other study ID #: 14-011236
• Secondary ID: U54NS115052U01NS
• Status: Recruiting
• Start date: December 8, 2016
• Est. completion date: December 8, 2030

Study information

• Verified date: December 2023
• Source: Children's Hospital of Philadelphia
• Contact: Omar S. Sherbini, MPH
• Phone: 215-590-3068
• Email: sherbinio[@]chop.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Description:

Genetic white matter disorders (leukodystrophies) are estimated to have an incidence of approximately 1:7000 live births. In the past, patients with white matter disease of unknown cause evaluated by the investigator achieved a diagnosis in fewer than 46% of cases after extensive conventional clinical testing. Even when a diagnosis is achieved, the diagnosis takes an average of eight years and this "odyssey" results in testing charges to patients and insurers in excess of $8,000 on average per patient, including patients who never achieve a diagnosis at all. With next generation approaches such as whole exome sequencing, the diagnostic efficacy is closer to 70%, but approximately a third of individuals do not achieve a specific etiologic diagnosis. These diagnostic challenges represent an urgent and unresolved gap in knowledge and disease characterization, as obtaining a definitive diagnosis is of paramount importance for leukodystrophy patients. Moreover, the mechanisms of disease in many leukodystrophies of known cause are very poorly understood, with little known about the best symptomatic management and, thus, limited standards of care are available for the management of these patients. The purpose of this study is to: (Aim 1) Define novel homogeneous groups of patients with unclassified leukodystrophy and work toward finding the cause of these disorders; (Aim 2) assess the validity and utility of next-generation sequencing in the diagnosis of leukodystrophies; (Aim 3) establish disease mechanisms in selected known leukodystrophies; (Aim 4) track current care and natural history of these patients to define the longitudinal course and determinants of outcomes in these disorders; (Aim 5) contact subjects for future research studies and/or clinical programs. This biorepository will use available basic science and clinical research approaches to establish novel diagnoses, biomarkers, and outcome measures for future clinical diagnostic and therapeutic approaches.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12000
• Est. completion date: December 8, 2030
• Est. primary completion date: December 8, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria (Affected Subjects):

• Male or female of any age;
• Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
• Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
• Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples. Exclusion Criteria (Affected Subjects)
• Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
• Inability to provide consent. Inclusion Criteria (Healthy Controls)
• Male or female of any age;
• Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
• Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent. Exclusion Criteria (Healthy Controls)
• Inability to provide consent.

Related Conditions & MeSH terms

• Adrenoleukodystrophy
• Adrenomyeloneuropathy
• Aicardi Goutieres Syndrome
• ALD
• ALD (Adrenoleukodystrophy)
• Alexander Disease
• Allan-Herndon-Dudley Syndrome
• ALSP
• AMN
• Cadasil
• Canavan Disease
• Charcot-Marie-Tooth
• Charcot-Marie-Tooth Disease
• CMT
• Cockayne Syndrome
• CTX
• Gangliosidoses
• Gangliosidoses, GM2
• GM2 Gangliosidosis
• Hereditary Sensory and Motor Neuropathy
• Intellectual Disability
• Krabbe Disease
• LBSL
• Leukodystrophy
• Leukodystrophy, Globoid Cell
• Leukodystrophy, Metachromatic
• Leukoencephalopathies
• Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation
• Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency
• Metachromatic Leukodystrophy
• MLD
• Mucopolysaccharidoses
• Multiple Sulfatase Deficiency Disease
• Nerve Compression Syndromes
• Pelizaeus-Merzbacher Disease
• Peroxisomal Disorders
• PMD
• Refsum Disease
• Sjogren's Syndrome
• Sjogren-Larsson Syndrome
• Syndrome
• Tay-Sachs Disease
• Vanishing White Matter Disease
• White Matter Disease
• X-ALD
• X-linked Adrenoleukodystrophy
• Xanthomatosis, Cerebrotendinous
• Zellweger Syndrome

Locations

Country	Name	City	State
United States	Emory University (Children's Healthcare of Atlanta)	Atlanta	Georgia
United States	Kennedy Krieger Institute	Baltimore	Maryland
United States	Massachusetts General Hospital (MGH)	Boston	Massachusetts
United States	Baylor College of Medicine (Texas Children's Hospital)	Houston	Texas
United States	Stanford University (Lucile Packard Children's Hospital)	Palo Alto	California
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Utah (Primary Children's Hospital)	Salt Lake City	Utah
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (19)

Lead Sponsor

Collaborator

Children's Hospital of Philadelphia

Affinia Therapeutics, Biogen, Boehringer Ingelheim, Eli Lilly and Company, Homology Medicines, Inc, Ionis Pharmaceuticals, Myrtelle Inc., National Center for Advancing Translational Sciences (NCATS), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Orchard Therapeutics Ltd., Passage Bio, Inc., Sana Biotechnology, Inc., Sanofi Winthrop Industrie, Synaptix Biotherapeutics Ltd., Takeda, University of Pennsylvania, Yaya Foundation for 4H Leukodystrophy

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Define Novel Homogeneous Groups of Patients with Unclassified Leukodystrophy	In patients with an unclassified leukodystrophy, the study team will collect as much information as available from existing medical records including existing clinical evaluations, neuropsychological/rehabilitation evaluations, and results from blood, urine, spinal fluid, radiological, and peripheral tissue pathological tests. This data will be evaluated to create nosologic groups amongst patients with unclassified leukodystrophy. Additionally, this aim includes the collection and long-term banking of biological samples in subjects with classified and unclassified leukodystrophies to develop a biorepository. These samples will be compared to samples collected from control subjects, either collected directly from enrolled subjects or through existing banked biological samples.	01/08/2016 - 01/08/2026
Secondary	Assess Validity of Next-Generation Sequencing in the Diagnosis of Leukodystrophies	Unclassified leukodystrophy patients enrolled in this study may undergo next generation sequencing approaches, including research whole exome sequencing (WES), whole genome sequencing (WGS), RNA sequencing and high throughput genomics analysis in parallel to standard clinical testing to achieve novel molecular classifications.	01/08/2016 - 01/08/2026
Secondary	Assess Utility of Next-Generation Sequencing in the Diagnosis of Leukodystrophies	Clinical utility defined as changes in care and clinical state, included changes in medical morbidities, surgeries, pharmacologic management of complications and implementation of disease specific therapies.	01/08/2016 - 01/08/2026
Secondary	Track Current Care of Leukodystrophy Patients	Includes a longitudinal collection of clinical data on diagnostic and therapeutic interventions in leukodystrophy patients and related controls.	01/08/2016 - 01/08/2026
Secondary	Track Natural History of Leukodystrophy Patients	Includes longitudinal collection of clinical data on disease presentation, progression and morbidities.	01/08/2016 - 01/08/2026
Secondary	Establish Disease Mechanisms in Leukodystrophies	Specific leukodystrophies will be selected for further mechanistic study, using clinical and laboratory tools to establish increased understanding of the underlying pathophysiology. The over-riding hypothesis of this aim is that integrated biochemical, genomic, metabolic, histologic and immunologic profiles of patients with leukodystrophy will define downstream pathway changes consistent with primary defects causing white matter disease. Appropriate controls will be used for comparison to disease related samples.	01/08/2016 - 01/08/2026
Secondary	Contact for Future Research Studies and/or Clinical Programs	Individuals enrolled in the study may be informed of other research studies, either at the Children's Hospital of Philadelphia or another site affiliated or not affiliated with this study, that may be of interest to them and/or their their families based on a specific diagnosis or lack thereof.	01/08/2016 - 01/08/2026